290 related articles for article (PubMed ID: 18195530)
1. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
[TBL] [Abstract][Full Text] [Related]
2. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics.
Sun Y; Duan Q; Wang S; Zeng Y; Wu R
J BUON; 2015; 20(2):452-9. PubMed ID: 26011335
[TBL] [Abstract][Full Text] [Related]
5. Single 20-second acquisition of deep-inspiration breath-hold PET/CT: clinical feasibility for lung cancer.
Torizuka T; Tanizaki Y; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Ouchi Y
J Nucl Med; 2009 Oct; 50(10):1579-84. PubMed ID: 19759111
[TBL] [Abstract][Full Text] [Related]
6. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.
Karam M; Ata A; Irish K; Feustel PJ; Mottaghy FM; Stroobants SG; Verhoef GE; Chundru S; Douglas-Nikitin V; Oliver Wong CY; Brepoels LM
Nucl Med Commun; 2009 Oct; 30(10):770-8. PubMed ID: 19657307
[TBL] [Abstract][Full Text] [Related]
7. Response to preoperative short-course radiotherapy in locally advanced rectal cancer: value of f-fluorodeoxyglucose positron emission tomography.
Siegel R; Dresel S; Koswig S; Gebauer B; Hunerbein M; Schneider W; Schlag PM
Onkologie; 2008 Apr; 31(4):166-72. PubMed ID: 18418017
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography with 2-deoxy-2-[18f] fluoro-D-glucose in the detection of malignancy in intraductal papillary mucinous neoplasms of the pancreas.
Goh BK; Chung YF; Ng DC; Selvarajan S; Soo KC
JOP; 2007 May; 8(3):350-4. PubMed ID: 17495366
[TBL] [Abstract][Full Text] [Related]
10. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography.
Bar-Shalom R; Kagna O; Israel O; Guralnik L
Cancer; 2008 Dec; 113(11):3213-21. PubMed ID: 18924145
[TBL] [Abstract][Full Text] [Related]
12. [The role of / 18FDG PET/CT for the initial staging and therapy in primary breast cancer].
Inokuchi M; Furukawa H; Kayahara M; Ohta T; Kawashima H; Taki J; Kinuya S
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2526-31. PubMed ID: 20009451
[TBL] [Abstract][Full Text] [Related]
13. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.
Kawada K; Murakami K; Sato T; Kojima Y; Ebi H; Mukai H; Tahara M; Shimokata K; Minami H
Jpn J Clin Oncol; 2007 Jan; 37(1):44-8. PubMed ID: 17060407
[TBL] [Abstract][Full Text] [Related]
15. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
Lewandowski RJ; Thurston KG; Goin JE; Wong CY; Gates VL; Van Buskirk M; Geschwind JF; Salem R
J Vasc Interv Radiol; 2005 Dec; 16(12):1641-51. PubMed ID: 16371530
[TBL] [Abstract][Full Text] [Related]
16. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers.
Haug AR; Schmidt GP; Klingenstein A; Heinemann V; Stieber P; Priebe M; la Fougère C; Becker C; Hahn K; Tiling R
J Comput Assist Tomogr; 2007; 31(4):629-34. PubMed ID: 17882045
[TBL] [Abstract][Full Text] [Related]
17. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL
J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757
[TBL] [Abstract][Full Text] [Related]
18. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer.
Chung MK; Jeong HS; Park SG; Jang JY; Son YI; Choi JY; Hyun SH; Park K; Ahn MJ; Ahn YC; Kim HJ; Ko YH; Baek CH
Clin Cancer Res; 2009 Sep; 15(18):5861-8. PubMed ID: 19737951
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy.
Yoon DH; Baek S; Choi CM; Lee DH; Suh C; Ryu JS; Moon DH; Lee JS; Kim SW
Clin Cancer Res; 2011 Aug; 17(15):5093-100. PubMed ID: 21673067
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
